Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Assets (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Return on Assets for 5 consecutive years, with 0.16% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Assets changed N/A year-over-year to 0.16%, compared with a TTM value of 0.16% through Dec 2025, changed N/A, and an annual FY2025 reading of 0.18%, up 56.0% over the prior year.
  • Return on Assets was 0.16% for Q4 2025 at Keros Therapeutics, up from 0.09% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.16% in Q4 2025 and bottomed at 0.49% in Q4 2023.
  • Average Return on Assets over 4 years is 0.2%, with a median of 0.24% recorded in 2021.
  • The sharpest move saw Return on Assets surged 40bps in 2021, then fell -13bps in 2022.
  • Year by year, Return on Assets stood at 0.24% in 2021, then tumbled by -55bps to 0.37% in 2022, then crashed by -30bps to 0.49% in 2023, then surged by 133bps to 0.16% in 2025.
  • Business Quant data shows Return on Assets for KROS at 0.16% in Q4 2025, 0.09% in Q3 2025, and 0.49% in Q4 2023.